0	5778152	761	892	Serum levels of total cholesterol (total cholesterol) and low-density lipoprotein cholesterol (low-density lipoprotein cholesterol)	Serum levels of total cholesterol (total cholesterol) and low-density lipoprotein cholesterol (low-density lipoprotein cholesterol) were decreased compared with the baseline values at 6 months in 6.5 and 14.0% of patients, respectively, receiving toremifene.
0	5778152	1020	1032	Lipid levels	Lipid levels did not change in patients administered letrozole.
0	5778152	1125	1182	total cholesterol and low-density lipoprotein cholesterol	Significant differences were observed in total cholesterol and low-density lipoprotein cholesterol between the two groups at 12 and 24 months.
0	5778152	1252	1329	serum bone-specific alkaline phosphatase (bone-specific alkaline phosphatase)	In the toremifene group, serum bone-specific alkaline phosphatase (bone-specific alkaline phosphatase) was decreased by 25.0% at 12 months, and serum cross-linked N-telopeptide of type-I collagen (NTx) was decreased by 13.6% at 6 months, and these reductions were maintained for at least 24 months.
0	5778152	1371	1428	serum cross-linked N-telopeptide of type-I collagen (NTx)	In the toremifene group, serum bone-specific alkaline phosphatase (bone-specific alkaline phosphatase) was decreased by 25.0% at 12 months, and serum cross-linked N-telopeptide of type-I collagen (NTx) was decreased by 13.6% at 6 months, and these reductions were maintained for at least 24 months.
0	3611754	941	973	intraoperative total fluid input	Chictr.org: ChiCTR-TRC-12002357 RESULTS: The patients who received the HS-HES solution had a significant decrease in the intraoperative total fluid input (p<0.01), the volume of Ringer's solution required (p<0.05), the fluid balance (p<0.01) and their dural tension scores (p<0.05).
0	3611754	988	1024	volume of Ringer's solution required	Chictr.org: ChiCTR-TRC-12002357 RESULTS: The patients who received the HS-HES solution had a significant decrease in the intraoperative total fluid input (p<0.01), the volume of Ringer's solution required (p<0.05), the fluid balance (p<0.01) and their dural tension scores (p<0.05).
0	3611754	1039	1052	fluid balance	Chictr.org: ChiCTR-TRC-12002357 RESULTS: The patients who received the HS-HES solution had a significant decrease in the intraoperative total fluid input (p<0.01), the volume of Ringer's solution required (p<0.05), the fluid balance (p<0.01) and their dural tension scores (p<0.05).
0	3611754	1072	1092	dural tension scores	Chictr.org: ChiCTR-TRC-12002357 RESULTS: The patients who received the HS-HES solution had a significant decrease in the intraoperative total fluid input (p<0.01), the volume of Ringer's solution required (p<0.05), the fluid balance (p<0.01) and their dural tension scores (p<0.05).
0	3611754	1107	1209	total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables	The total urine output, blood loss, bleeding severity scores, operation duration and hemodynamic variables were similar in both groups (p>0.05).
0	3611754	1345	1416	plasma concentrations of sodium and chloride, increasing the osmolality	Moreover, compared with the hydroxyethyl starch group, the HS-HES group had significantly higher plasma concentrations of sodium and chloride, increasing the osmolality (p<0.01).  
0	3611754	1657	1677	dural tension scores	Moreover, HS-HES improved the dural tension scores and provided satisfactory brain relaxation.
0	3611754	1691	1721	satisfactory brain relaxation.	Moreover, HS-HES improved the dural tension scores and provided satisfactory brain relaxation.
0	5852732	1015	1061	showed significantly lower BMI-for-age z-score	Results: IG showed significantly lower BMI-for-age z-score (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p < 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to CG.
0	5852732	1115	1144	= 0.009), body fat percentage	Results: IG showed significantly lower BMI-for-age z-score (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p < 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to CG.
0	5852732	1203	1228	) and waist circumference	Results: IG showed significantly lower BMI-for-age z-score (weighted difference: −0.12; 95% CI: −0.21, −0.03; p = 0.009), body fat percentage (weighted difference: −2.6%; 95% CI: −3.7, −1.5; p < 0.001) and waist circumference (weighted difference: −2.4 cm; 95% CI: −3.8, −1.0; p = 0.001) compared to CG.
0	5852732	1333	1358	lower body fat percentage	IG reported significantly lower body fat percentage (weighted difference: −3.4%; 95% CI: 1.8, 5.0; p < 0.001) and waist circumference (weighted difference: −2.1 cm; 95% CI: −3.7, −0.5; p = 0.014) at T1 compared to T0.
0	5852732	1421	1440	waist circumference	IG reported significantly lower body fat percentage (weighted difference: −3.4%; 95% CI: 1.8, 5.0; p < 0.001) and waist circumference (weighted difference: −2.1 cm; 95% CI: −3.7, −0.5; p = 0.014) at T1 compared to T0.
0	4734812	875	902	Results Mean blood pressure	Results Mean blood pressure was significantly reduced by 5.0±2.1 mmHg (P=0.016) systolic, and in responders by 11.5±1.9 mmHg systolic and 6.3±1.1 mmHg diastolic compared to placebo (P<0.001).
0	4734812	1064	1066	).	Results Mean blood pressure was significantly reduced by 5.0±2.1 mmHg (P=0.016) systolic, and in responders by 11.5±1.9 mmHg systolic and 6.3±1.1 mmHg diastolic compared to placebo (P<0.001).
0	4734812	1067	1095	Central hemodynamic-measures	Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.
0	4734812	1176	1315	central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.	Central hemodynamic-measures tended to improve in the garlic group more than in the placebo group, including central blood pressure, central pulse pressure, mean arterial pressure, augmentation pressure, pulse-wave velocity, and arterial stiffness.
0	4734812	1627	1658	highly tolerable and acceptable	Aged garlic extract was highly tolerable and acceptable, and did not increase the risk of bleeding in patients on blood-thinning medication.  
0	4734812	1685	1701	risk of bleeding	Aged garlic extract was highly tolerable and acceptable, and did not increase the risk of bleeding in patients on blood-thinning medication.  
0	1829425	1098	1106	“Assess”	Measurements and Main Results Intervention physicians exceeded controls on “Assess” (OR 5.06; 95% CI 3.22, 7.95), “Advise” (OR 2.79; 95% CI 1.70, 4.59), “Assist–set goals” (OR 4.31; 95% CI 2.59, 7.16), “Assist–provide written materials” (OR 5.14; 95% CI 2.60, 10.14), “
0	1829425	1137	1145	“Advise”	Measurements and Main Results Intervention physicians exceeded controls on “Assess” (OR 5.06; 95% CI 3.22, 7.95), “Advise” (OR 2.79; 95% CI 1.70, 4.59), “Assist–set goals” (OR 4.31; 95% CI 2.59, 7.16), “Assist–provide written materials” (OR 5.14; 95% CI 2.60, 10.14), “
0	1829425	1176	1194	“Assist–set goals”	Measurements and Main Results Intervention physicians exceeded controls on “Assess” (OR 5.06; 95% CI 3.22, 7.95), “Advise” (OR 2.79; 95% CI 1.70, 4.59), “Assist–set goals” (OR 4.31; 95% CI 2.59, 7.16), “Assist–provide written materials” (OR 5.14; 95% CI 2.60, 10.14), “
0	1829425	1225	1259	“Assist–provide written materials”	Measurements and Main Results Intervention physicians exceeded controls on “Assess” (OR 5.06; 95% CI 3.22, 7.95), “Advise” (OR 2.79; 95% CI 1.70, 4.59), “Assist–set goals” (OR 4.31; 95% CI 2.59, 7.16), “Assist–provide written materials” (OR 5.14; 95% CI 2.60, 10.14), “
0	1829425	1291	1316	“Assist–provide referral”	Measurements and Main Results Intervention physicians exceeded controls on “Assess” (OR 5.06; 95% CI 3.22, 7.95), “Advise” (OR 2.79; 95% CI 1.70, 4.59), “Assist–set goals” (OR 4.31; 95% CI 2.59, 7.16), “Assist–provide written materials” (OR 5.14; 95% CI 2.60, 10.14), “
0	1829425	1291	1316	“Assist–provide referral”	Assist–provide referral” (OR 6.48; 95% CI 3.11, 13.49), “
0	1829425	1348	1375	“Assist–discuss medication”	Assist–provide referral” (OR 6.48; 95% CI 3.11, 13.49), “
0	1829425	1348	1375	“Assist–discuss medication”	Assist–discuss medication” (OR 4.72;95% CI 2.90, 7.68), and “Arrange” (OR 8.14; 95% CI 3.98, 16.68), all p values being < 0.0001.
0	1829425	1575	1584	abstinent	Intervention patients were 1.77 (CI 0.94, 3.34,p = 0.078) times more likely than controls to be abstinent (12 versus 8%), a difference that approached, but did not reach statistical significance, and surpassed controls on number of days quit (18.4 versus 12.2, p < .05) but not on number of quit attempts.  
0	1829425	1701	1720	number of days quit	Intervention patients were 1.77 (CI 0.94, 3.34,p = 0.078) times more likely than controls to be abstinent (12 versus 8%), a difference that approached, but did not reach statistical significance, and surpassed controls on number of days quit (18.4 versus 12.2, p < .05) but not on number of quit attempts.  
0	1829425	1760	1784	number of quit attempts.	Intervention patients were 1.77 (CI 0.94, 3.34,p = 0.078) times more likely than controls to be abstinent (12 versus 8%), a difference that approached, but did not reach statistical significance, and surpassed controls on number of days quit (18.4 versus 12.2, p < .05) but not on number of quit attempts.  
0	4706860	778	829	peak torque (Nm), total work (J), or mean power (W)	Testing concentric contractions at 60°/s or 180°/s isokinetic speed, no significant differences in peak torque (Nm), total work (J), or mean power (W) were noted among the application modes under different conditions.
0	4706860	1106	1121	muscle strength	Kinesio Taping on the quadriceps neither decreased nor increased muscle strength in the participants.  
0	4706860	1250	1285	strength or power of knee extensors	Kinesio Taping application onto the skin overlying the quadriceps muscle does not enhance the strength or power of knee extensors in healthy men.
0	5754509	1309	1345	Results Baseline median (IQR) levels	Results Baseline median (IQR) levels were as follows: Midregional-pro-adrenomedullin 0.52 (0.45–0.56) nmol/L, midregional-pro-atrial natriuretic peptide 44.8 (34.6–56.7) pmol/L and copeptin 4.95 (3.50–6.50) pmol/L. Mean percentage differences (95% CI) between liraglutide and placebo group after treatment were as follows: Midregional-pro-adrenomedullin −6% (−11 to 2, P = 0.058), midregional-pro-atrial natriuretic peptide −25% (−37 to −11, P = 0.001) and copeptin +4% (−13 to 25, P = 0.64).
0	5754509	1815	1871	midregional-pro-atrial natriuretic peptide concentration	Reduction in midregional-pro-atrial natriuretic peptide concentration correlated with both increased heart rate and diastolic blood pressure in the liraglutide group.
0	5754509	1903	1942	heart rate and diastolic blood pressure	Reduction in midregional-pro-atrial natriuretic peptide concentration correlated with both increased heart rate and diastolic blood pressure in the liraglutide group.
0	5754509	2117	2159	midregional-pro-atrial natriuretic peptide	Multiple regression analyses with adjustment for BMI, free testosterone, insulin resistance, visceral fat, heart rate and eGFR showed reductions in midregional-pro-atrial natriuretic peptide to be independently correlated with an increase in the heart rate.  
0	5754509	2215	2226	heart rate.	Multiple regression analyses with adjustment for BMI, free testosterone, insulin resistance, visceral fat, heart rate and eGFR showed reductions in midregional-pro-atrial natriuretic peptide to be independently correlated with an increase in the heart rate.  
0	5754509	2320	2407	levels of the cardiovascular risk biomarkers midregional-pro-atrial natriuretic peptide	Conclusion In an RCT, liraglutide treatment in women with polycystic ovary syndrome reduced levels of the cardiovascular risk biomarkers midregional-pro-atrial natriuretic peptide with 25% and Midregional-pro-adrenomedullin with 6% (borderline significance) compared with placebo.
0	5754509	2421	2451	Midregional-pro-adrenomedullin	Conclusion In an RCT, liraglutide treatment in women with polycystic ovary syndrome reduced levels of the cardiovascular risk biomarkers midregional-pro-atrial natriuretic peptide with 25% and Midregional-pro-adrenomedullin with 6% (borderline significance) compared with placebo.
0	5754509	2525	2567	midregional-pro-atrial natriuretic peptide	The decrease in midregional-pro-atrial natriuretic peptide was independently associated with an increase in the heart rate.
0	5754509	2621	2632	heart rate.	The decrease in midregional-pro-atrial natriuretic peptide was independently associated with an increase in the heart rate.
0	5328251	1007	1034	successful preparation rate	In per-protocol analysis, patients in group B attained significantly higher successful preparation rate than group A (88.7% vs. 61.2%, p<0.001) and similar with group C (88.7% vs. 85.0%, p = 0.316).
0	5328251	1134	1154	polyp detection rate	The polyp detection rate in group B was significantly higher than group A (43.2% vs. 25.7%, p<0.001).
0	5328251	1232	1245	Acceptability	Acceptability was much higher in group B and C.  Conclusions 10 mg bisacodyl plus 2 L PEG-ELP can significantly improve both bowel preparation quality and polyp detection rate in patients with Bristol stool form 1 and 2.
0	5328251	1357	1407	bowel preparation quality and polyp detection rate	Acceptability was much higher in group B and C.  Conclusions 10 mg bisacodyl plus 2 L PEG-ELP can significantly improve both bowel preparation quality and polyp detection rate in patients with Bristol stool form 1 and 2.
0	3770019	609	627	of ≥5% weight loss	The subject response rate of ≥5% weight loss compared to baseline was similar in both groups, and no statistically significant difference was observed (P = 0.87).
0	3770019	757	782	anthropometric parameters	Changes in anthropometric parameters were greater during the first 4 weeks in the treatment group (P < 0.0001).
0	3770019	937	976	lipid profile and body fat composition.	There were no significant changes in both within groups and between groups for lipid profile and body fat composition.
0	3770019	980	993	adverse event	No adverse event was reported in either group.
0	3770019	1091	1116	rate of subjects who lost	Although the difference between the groups regarding a rate of subjects who lost 5% or more of initial weight did not show statistical significance, TJ001 appears to be beneficial in safely controlling weight.
0	3770019	1226	1245	controlling weight.	Although the difference between the groups regarding a rate of subjects who lost 5% or more of initial weight did not show statistical significance, TJ001 appears to be beneficial in safely controlling weight.
0	5844531	1375	1392	improve retention	The Family Clinic Day did not improve retention (aOR 1.11; 90% CI 0.63–1.97, p = 0.75), but was associated with improved adherence to last appointment schedule (aOR 1.64; 90% CI 1.27–2.11, p<0.001).
0	5844531	1441	1504	associated with improved adherence to last appointment schedule	The Family Clinic Day did not improve retention (aOR 1.11; 90% CI 0.63–1.97, p = 0.75), but was associated with improved adherence to last appointment schedule (aOR 1.64; 90% CI 1.27–2.11, p<0.001).
0	3701849	754	792	Alanine aminotransferase normalization	The Alanine aminotransferase normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001).
0	3701849	885	928	Alanine aminotransferase normalization rate	Alanine aminotransferase normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019).
0	3701849	1204	1215	HBsAg level	Quantification of HBsAg level was not different from the monotherapy to combination at 12 months.
0	3701849	1321	1340	the INF-γ secretion	Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment.  
0	3701849	1441	1484	Alanine aminotransferase normalization rate	Conclusions Alanine aminotransferase normalization rate was higher in carnitine complex combination group than entecavir group in Chronic Hepatitis B. Combination group was faster than entecavir mono-treatment group on Alanine aminotransferase normalization rate.
0	3701849	1648	1692	Alanine aminotransferase normalization rate.	Conclusions Alanine aminotransferase normalization rate was higher in carnitine complex combination group than entecavir group in Chronic Hepatitis B. Combination group was faster than entecavir mono-treatment group on Alanine aminotransferase normalization rate.
0	3701849	1693	1747	HBV DNA normalization rate and the serum HBV-DNA level	HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment.
0	3621765	1191	1227	better Mini-Mental State Examination	A sub-analysis of amnestic mild cognitive impairment patients for group × time interactions revealed that the exercise group exhibited significantly better Mini-Mental State Examination (p = .04) and logical memory scores (p = .04), and reducing whole brain cortical atrophy (p<.05) compared to the control group.
0	3621765	1238	1263	and logical memory scores	A sub-analysis of amnestic mild cognitive impairment patients for group × time interactions revealed that the exercise group exhibited significantly better Mini-Mental State Examination (p = .04) and logical memory scores (p = .04), and reducing whole brain cortical atrophy (p<.05) compared to the control group.
0	3621765	1288	1316	whole brain cortical atrophy	A sub-analysis of amnestic mild cognitive impairment patients for group × time interactions revealed that the exercise group exhibited significantly better Mini-Mental State Examination (p = .04) and logical memory scores (p = .04), and reducing whole brain cortical atrophy (p<.05) compared to the control group.
0	3621765	1360	1384	total cholesterol levels	Low total cholesterol levels before the intervention were associated with an improvement of logical memory scores (p<.05), and a higher level of brain-derived neurotrophic factor was significantly related to improved ADAS-cog scores (p<.05).  
0	3621765	1448	1469	logical memory scores	Low total cholesterol levels before the intervention were associated with an improvement of logical memory scores (p<.05), and a higher level of brain-derived neurotrophic factor was significantly related to improved ADAS-cog scores (p<.05).  
0	3621765	1492	1534	level of brain-derived neurotrophic factor	Low total cholesterol levels before the intervention were associated with an improvement of logical memory scores (p<.05), and a higher level of brain-derived neurotrophic factor was significantly related to improved ADAS-cog scores (p<.05).  
0	3621765	1564	1588	improved ADAS-cog scores	Low total cholesterol levels before the intervention were associated with an improvement of logical memory scores (p<.05), and a higher level of brain-derived neurotrophic factor was significantly related to improved ADAS-cog scores (p<.05).  
0	5815423	1024	1033	pain-free	Results Of patients treated with Adhesive Dermally-Applied Microarray zolmitriptan 3.8 mg or placebo, 41.5% and 14.2%, respectively were pain-free 2 hours post-dose (p = 0.0001) and 68.3% and 42.9% were free from their most bothersome other symptom (p = 0.0009).
0	5815423	1106	1135	most bothersome other symptom	Results Of patients treated with Adhesive Dermally-Applied Microarray zolmitriptan 3.8 mg or placebo, 41.5% and 14.2%, respectively were pain-free 2 hours post-dose (p = 0.0001) and 68.3% and 42.9% were free from their most bothersome other symptom (p = 0.0009).
0	5815423	1321	1372	photophobia-free, phonophobia-free, and nausea-free	However, the proportion of patients who were photophobia-free, phonophobia-free, and nausea-free at 2 hours post-dose was higher in the Adhesive Dermally-Applied Microarray zolmitriptan 3.8 mg group compared with placebo, as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.
0	5815423	1543	1552	pain-free	However, the proportion of patients who were photophobia-free, phonophobia-free, and nausea-free at 2 hours post-dose was higher in the Adhesive Dermally-Applied Microarray zolmitriptan 3.8 mg group compared with placebo, as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.
0	5815423	1574	1585	pain relief	However, the proportion of patients who were photophobia-free, phonophobia-free, and nausea-free at 2 hours post-dose was higher in the Adhesive Dermally-Applied Microarray zolmitriptan 3.8 mg group compared with placebo, as were the percentages of patients who were pain-free, and who experienced pain relief up to 48 hours post-dose.
0	5815423	2048	2075	relief of migraine headache	Conclusion Adhesive Dermally-Applied Microarray zolmitriptan 3.8 mg provides effective relief of migraine headache and associated most bothersome symptoms compared with placebo, and is well-tolerated.  
0	5815423	2091	2115	most bothersome symptoms	Conclusion Adhesive Dermally-Applied Microarray zolmitriptan 3.8 mg provides effective relief of migraine headache and associated most bothersome symptoms compared with placebo, and is well-tolerated.  
0	4132277	749	762	larger stones	Group I patients have larger stones as Group II (10.70 mm vs. 8.24 mm, respectively, P = 0.020).  
0	4132277	833	856	Overall stone free rate	Results Overall stone free rate for both groups was 95.8%.
0	4132277	884	913	The mean number of procedures	The mean number of procedures for proximal calculi was 1.1 ± 0.1 (1–3) and for distal calculi was 1.0 ± 0.0.
0	4132277	1153	1168	stone free rate	No significant difference in the stone free rate was noticed after the second laser procedure for stones smaller versus larger than 10 mm (100% versus 94.1%, P = 0.13).
0	4132277	1289	1314	Overall complication rate	Overall complication rate was 7.9% (Clavien II und IIIb).
0	4132277	1347	1392	Overall and grade-adjusted complication rates	Overall and grade-adjusted complication rates were not dependant on the stone location.
0	4132277	1438	1465	laser induced complications	No laser induced complications were noticed.  
0	546286	1037	1042	CTX-I	Treatment with hormone replacement therapy resulted in decrease in CTX-I (P < 0.001), ICTP (P < 0.001), PICP (P < 0.05), cartilage oligomeric matrix protein (P < 0.01), and CTX-II (P < 0.05) at 2 years.
0	546286	1056	1060	ICTP	Treatment with hormone replacement therapy resulted in decrease in CTX-I (P < 0.001), ICTP (P < 0.001), PICP (P < 0.05), cartilage oligomeric matrix protein (P < 0.01), and CTX-II (P < 0.05) at 2 years.
0	546286	1074	1078	PICP	Treatment with hormone replacement therapy resulted in decrease in CTX-I (P < 0.001), ICTP (P < 0.001), PICP (P < 0.05), cartilage oligomeric matrix protein (P < 0.01), and CTX-II (P < 0.05) at 2 years.
0	546286	1091	1126	cartilage oligomeric matrix protein	Treatment with hormone replacement therapy resulted in decrease in CTX-I (P < 0.001), ICTP (P < 0.001), PICP (P < 0.05), cartilage oligomeric matrix protein (P < 0.01), and CTX-II (P < 0.05) at 2 years.
0	546286	1143	1149	CTX-II	Treatment with hormone replacement therapy resulted in decrease in CTX-I (P < 0.001), ICTP (P < 0.001), PICP (P < 0.05), cartilage oligomeric matrix protein (P < 0.01), and CTX-II (P < 0.05) at 2 years.
0	546286	1187	1208	CTX-I, ICTP, and PICP	Reductions in CTX-I, ICTP, and PICP were associated with improved bone mineral density.
0	546286	1239	1260	bone mineral density.	Reductions in CTX-I, ICTP, and PICP were associated with improved bone mineral density.
0	546286	1300	1313	bone turnover	Of the markers tested, CTX-I reflected bone turnover most sensitively; it was reduced by 53 ± 6% in the patients receiving hormone replacement therapy.
0	546286	1413	1426	Baseline ICTP	Baseline ICTP (P < 0.001), CTX-II (P < 0.01), and cartilage oligomeric matrix protein (P < 0.05) correlated with the Larsen score.
0	546286	1440	1446	CTX-II	Baseline ICTP (P < 0.001), CTX-II (P < 0.01), and cartilage oligomeric matrix protein (P < 0.05) correlated with the Larsen score.
0	546286	1463	1498	cartilage oligomeric matrix protein	Baseline ICTP (P < 0.001), CTX-II (P < 0.01), and cartilage oligomeric matrix protein (P < 0.05) correlated with the Larsen score.
0	3575556	989	998	compliant	Results Patients were significantly more compliant when using the S9 than their usual continuous positive airway pressure device both pre- and post-S9 based on average daily usage.
0	3575556	1129	1171	continuous positive airway pressure pre-S9	continuous positive airway pressure pre-S9 = 6.58 ± 1.95 (mean hours ± SD), S9 = 7.08 ± 1.18 h and continuous positive airway pressure post-S9 = 6.71 ± 1.72 h.
0	3575556	1228	1263	continuous positive airway pressure	continuous positive airway pressure pre-S9 = 6.58 ± 1.95 (mean hours ± SD), S9 = 7.08 ± 1.18 h and continuous positive airway pressure post-S9 = 6.71 ± 1.72 h.
0	3575556	1526	1568	continuous positive airway pressure pre-S9	There was no significant difference between continuous positive airway pressure pre-S9 and continuous positive airway pressure post-S9 (p = 0.34).
0	3575556	1573	1608	continuous positive airway pressure	There was no significant difference between continuous positive airway pressure pre-S9 and continuous positive airway pressure post-S9 (p = 0.34).
0	3575556	1824	1833	compliant	Conclusions Participants were significantly more compliant when using the S9 than their usual continuous positive airway pressure device both pre- and post-S9 use.
0	3510746	1600	1609	Attrition	Attrition was similar in groups 1 (697/1742, 40.01%) and 2 (737/1742, 42.31% retained) and lower in group 3 (902/1743, 51.75% retained).
0	3616846	1030	1070	characteristics and mean (range) intakes	Results Baseline characteristics and mean (range) intakes of fish [21 (0–125) g/day] and docosahexaenoic acid from fish [91 (0–554) mg/d] were similar in all 3 arms.
0	3616846	1102	1117	docosahexaenoic	Results Baseline characteristics and mean (range) intakes of fish [21 (0–125) g/day] and docosahexaenoic acid from fish [91 (0–554) mg/d] were similar in all 3 arms.
0	3616846	1207	1221	intake of fish	From baseline to follow-up, intake of fish [Advice: 12 g/day (95% CI: -5, 29), Advice+GC: 22 g/day (5, 39)] and docosahexaenoic acid [Advice: 70 mg/d (3, 137), Advice+GC: 161 mg/d (93, 229)] increased in both intervention groups, compared with controls.
0	3616846	1291	1311	docosahexaenoic acid	From baseline to follow-up, intake of fish [Advice: 12 g/day (95% CI: -5, 29), Advice+GC: 22 g/day (5, 39)] and docosahexaenoic acid [Advice: 70 mg/d (3, 137), Advice+GC: 161 mg/d (93, 229)] increased in both intervention groups, compared with controls.
0	3616846	1643	1657	mercury intake	We did not detect any differences in mercury intake or in biomarker levels of mercury and docosahexaenoic acid between groups.  
0	3616846	1664	1716	biomarker levels of mercury and docosahexaenoic acid	We did not detect any differences in mercury intake or in biomarker levels of mercury and docosahexaenoic acid between groups.  
0	3616846	1784	1828	consumption of fish and docosahexaenoic acid	Conclusions An educational intervention increased consumption of fish and docosahexaenoic acid but not mercury.
0	1543618	943	962	Results CAPS-scores	Results CAPS-scores showed significantly greater improvement in the cognitive behavioral treatment condition as compared to the wait list condition (group × time interaction effect size d = 1.61).
0	1543618	1237	1254	clinical recovery	Categorical diagnostic data indicated clinical recovery of 67% (post-treatment) and 76% (3 months FU) in the treatment group.
0	1543618	1439	1465	co-morbid major depression	Additionally, patients of the cognitive behavioral treatment condition showed significantly greater reductions in co-morbid major depression than the control condition.
0	3532098	1210	1230	minor adverse events	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the Platelet Rich Plasma group, where a significantly higher post-injective pain reaction was observed (p=0.039).
0	3532098	1271	1293	mild pain and effusion	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the Platelet Rich Plasma group, where a significantly higher post-injective pain reaction was observed (p=0.039).
0	3532098	1394	1422	post-injective pain reaction	Results Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the Platelet Rich Plasma group, where a significantly higher post-injective pain reaction was observed (p=0.039).
0	3532098	1501	1521	clinical improvement	At the follow-up evaluations, both groups presented a clinical improvement but the comparison between the two groups showed a not statistically significant difference in all scores evaluated.
0	4591119	1660	1685	incidence of heart attack	Results Relative to the standard care, receiving KM2H2 was associated with significant reductions in the incidence of heart attack (3.60% vs. 7.03%, p < .05) and stroke (5.11% vs. 9.90%, p<0.05), and moderate reduction in blood pressure (-3.72mmHg in DBP and -2.92 mmHg in DBP) at 6-month post-intervention; and significant increases in physical activity at 3- (d = 0.53, 95% CI: 0.21, 0.85) and 6-month (d = 0.45, 95% CI: 0.04, 0.85) post-intervention, respectively.  
0	4591119	1717	1723	stroke	Results Relative to the standard care, receiving KM2H2 was associated with significant reductions in the incidence of heart attack (3.60% vs. 7.03%, p < .05) and stroke (5.11% vs. 9.90%, p<0.05), and moderate reduction in blood pressure (-3.72mmHg in DBP and -2.92 mmHg in DBP) at 6-month post-intervention; and significant increases in physical activity at 3- (d = 0.53, 95% CI: 0.21, 0.85) and 6-month (d = 0.45, 95% CI: 0.04, 0.85) post-intervention, respectively.  
0	4591119	1777	1791	blood pressure	Results Relative to the standard care, receiving KM2H2 was associated with significant reductions in the incidence of heart attack (3.60% vs. 7.03%, p < .05) and stroke (5.11% vs. 9.90%, p<0.05), and moderate reduction in blood pressure (-3.72mmHg in DBP and -2.92 mmHg in DBP) at 6-month post-intervention; and significant increases in physical activity at 3- (d = 0.53, 95% CI: 0.21, 0.85) and 6-month (d = 0.45, 95% CI: 0.04, 0.85) post-intervention, respectively.  
0	4591119	1892	1909	physical activity	Results Relative to the standard care, receiving KM2H2 was associated with significant reductions in the incidence of heart attack (3.60% vs. 7.03%, p < .05) and stroke (5.11% vs. 9.90%, p<0.05), and moderate reduction in blood pressure (-3.72mmHg in DBP and -2.92 mmHg in DBP) at 6-month post-intervention; and significant increases in physical activity at 3- (d = 0.53, 95% CI: 0.21, 0.85) and 6-month (d = 0.45, 95% CI: 0.04, 0.85) post-intervention, respectively.  
0	3621886	760	811	mean absolute change (SD) in flow-mediated dilation	Results The difference in mean absolute change (SD) in flow-mediated dilation after 8 weeks between the placebo [−1.06 (1.45)%] and pentoxifylline [−1.93 (3.03)%] groups was not significant (P = 0.44).
0	3621886	954	985	Nitroglycerin-mediated dilation	No differences in Nitroglycerin-mediated dilation were observed.
0	3621886	1054	1075	changes in biomarkers	The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 (sTNFRI) [−83.2 pg/mL in the placebo group vs. +65.9 pg/mL in the pentoxifylline group; P = 0.03].
0	3621886	1104	1156	in soluble tumor necrosis factor receptor-1 (sTNFRI)	The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 (sTNFRI) [−83.2 pg/mL in the placebo group vs. +65.9 pg/mL in the pentoxifylline group; P = 0.03].
0	3621886	1236	1246	P = 0.03].	The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 (sTNFRI) [−83.2 pg/mL in the placebo group vs. +65.9 pg/mL in the pentoxifylline group; P = 0.03].
0	3621886	1276	1291	well-tolerated.	pentoxifylline was generally well-tolerated.  
0	3621886	1336	1356	endothelial function	Conclusions pentoxifylline did not improve endothelial function and unexpectedly increased the inflammatory biomarker sTNFRI in HIV-infected participants not requiring antiretroviral therapy.
0	3621886	1388	1417	inflammatory biomarker sTNFRI	Conclusions pentoxifylline did not improve endothelial function and unexpectedly increased the inflammatory biomarker sTNFRI in HIV-infected participants not requiring antiretroviral therapy.
0	5398527	1340	1363	child dietary diversity	A positive impact on child dietary diversity was observed (B (SE) = 0.39 (0.15), p = 0.01; 95%CI 0.09–0.68).
0	5398527	1478	1516	effect on mean height-for-age z-scores	There was a non-significant positive intervention effect on mean height-for-age z-scores (B (SE) = 0.17 (0.12), p = 0.15; 95%CI -0.06–0.41).
0	3757794	804	813	IDS score	Results: The IDS score was low and comparable between the two laryngoscopes.
0	3757794	872	886	laryngeal view	The laryngeal view was easy; Modified Cormack Lehane (Modified Cormack Lehane) grade 2a or less in 98.14% of the cases with the Truview laryngoscope compared to 78.7% of the cases with the Macintosh laryngoscope.
0	3757794	891	955	easy; Modified Cormack Lehane (Modified Cormack Lehane) grade 2a	The laryngeal view was easy; Modified Cormack Lehane (Modified Cormack Lehane) grade 2a or less in 98.14% of the cases with the Truview laryngoscope compared to 78.7% of the cases with the Macintosh laryngoscope.
0	3757794	1300	1326	The duration of intubation	The duration of intubation was comparable between Truview and Macintosh laryngoscopes (12.1±3.8 s vs. 10.9±2.1 s).  
0	5557997	933	960	mean push-out bond strength	Results: There was a significant difference in the mean push-out bond strength among the groups (P<0.05).
0	5557997	999	1012	bond strength	The lowest bond strength was noted in the control group.
0	5557997	1148	1161	bond strength	The bond strength of Endsolv R group increased; however, it was not significant (P>0.05).  
0	3823877	1319	1330	mean scores	Patients in the video group had 19% higher mean scores (2.5, s.d.
0	3823877	1525	1544	fully correct score	After adjustment for patient age, sex, first language, triage acuity score, and clustering, the odds of achieving a fully correct score (3 out of 3) were 3.5 (95% CI, 1.7 to 7.2) times higher in the video group, compared to the control group.
0	3823877	1687	1714	median rating of the videos	Among those who viewed the videos, median rating of the videos was 10 (IQR 8 to 10).  
0	3823877	1870	1943	understanding of key concepts around their diagnosis and subsequent care.	Conclusions In this single-center trial, patients who viewed an online video of their discharge instructions scored higher on their understanding of key concepts around their diagnosis and subsequent care.
0	4557407	1458	1499	anxiety level and hemodynamic parameters.	Results: Before the intervention, the study groups did not differ significantly in terms of anxiety level and hemodynamic parameters.
0	4557407	1560	1582	hemodynamic parameters	Moreover, the differences between the two groups, regarding hemodynamic parameters, were not significant after the intervention (P > 0.05).
0	4557407	1640	1687	However, the level of post-intervention anxiety	However, the level of post-intervention anxiety in the experimental group was significantly lower than the control group (32.06 ± 8.57 and 38.97 ± 12.77, respectively; P = 0.014).
0	4557407	1855	1877	, the level of anxiety	Compared with the baseline readings, the level of anxiety in the control group did not change significantly after the study (41.91 ± 9.88 vs. 38.97 ± 12.77; P = 0.101); however, in the experimental group, the level of post-intervention anxiety was significantly lower than the pretest readings (32.06 ± 8.57 vs. 41.16 ± 10.6; P = 0.001).  
0	4557407	2023	2063	, the level of post-intervention anxiety	Compared with the baseline readings, the level of anxiety in the control group did not change significantly after the study (41.91 ± 9.88 vs. 38.97 ± 12.77; P = 0.101); however, in the experimental group, the level of post-intervention anxiety was significantly lower than the pretest readings (32.06 ± 8.57 vs. 41.16 ± 10.6; P = 0.001).  
0	4557407	2155	2157	).	Compared with the baseline readings, the level of anxiety in the control group did not change significantly after the study (41.91 ± 9.88 vs. 38.97 ± 12.77; P = 0.101); however, in the experimental group, the level of post-intervention anxiety was significantly lower than the pretest readings (32.06 ± 8.57 vs. 41.16 ± 10.6; P = 0.001).  
0	5557574	1263	1285	mean arterial pressure	Results A higher proportion of the patients receiving 2.5 ng/kg/minute selepressin maintained mean arterial pressure >60 mmHg without norepinephrine (about 50% and 70% at 12 and 24 h, respectively) vs. 1.25 ng/kg/minute selepressin and placebo (p < 0.01).
0	5557574	1869	1897	Cumulative net fluid balance	Cumulative net fluid balance was lower from day 5 onward in the selepressin 2.5 ng/kg/minute group vs. placebo (p < 0.05).
0	5557574	2045	2093	proportion of days alive and free of ventilation	The selepressin 2.5 ng/kg/minute group had a greater proportion of days alive and free of ventilation vs. placebo (p < 0.02).
0	5557574	2158	2167	tolerated	Selepressin (2.5 ng/kg/minute) was well tolerated, with a similar frequency of treatment-emergent adverse events for selepressin 2.5 ng/kg/minute and placebo.
0	5557574	2197	2230	treatment-emergent adverse events	Selepressin (2.5 ng/kg/minute) was well tolerated, with a similar frequency of treatment-emergent adverse events for selepressin 2.5 ng/kg/minute and placebo.
0	3757792	1037	1163	Patient characteristics and baseline values of Heart rate, mean arterial pressure, perfusion index and pleth variability index	Results: Patient characteristics and baseline values of Heart rate, mean arterial pressure, perfusion index and pleth variability index were comparable between the groups.
0	3757792	1281	1296	perfusion index	Hypercapnia significantly increased perfusion index and decreased pleth variability index with significant negative correlation.  
0	3757792	1311	1334	pleth variability index	Hypercapnia significantly increased perfusion index and decreased pleth variability index with significant negative correlation.  
0	3757792	1413	1443	pleth variability index values	Conclusion: Hypercapnia retracts back pleth variability index values compared with normocapnia.
0	79000	687	743	Plasma low density lipoprotein-cholesterol concentration	Results Plasma low density lipoprotein-cholesterol concentration fell 7%, 39% (p < 0.01 vs baseline) and 47% (p < 0.01 vs baseline) after 12 weeks of treatment with placebo, simvastatin 20 mg and 40 mg, respectively.
0	79000	909	935	bone marker concentrations	At baseline, bone marker concentrations were similar in the three treatment groups.
0	79000	999	1025	bone marker concentrations	At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.  
0	79000	1094	1120	bone marker concentrations	At 6 and 12 weeks, bone marker concentrations were not different from baseline, and no significant differences in bone marker concentrations were observed between treatment groups at either 6 or 12 weeks.  
0	79000	1276	1316	markers of bone formation or resorption.	Conclusion Among osteopenic women, treatment with simvastatin for 12 weeks did not affect markers of bone formation or resorption.
0	3682318	1313	1344	Colonization of insertion sites	Results Colonization of insertion sites was not affected by the use of medical-grade honey, as 44 (34%) of 129 and 36 (34%) of 106 patients in the honey and standard care groups, respectively, had a positive skin culture (P = 0.98).
0	3682318	1504	1525	positive skin culture	Results Colonization of insertion sites was not affected by the use of medical-grade honey, as 44 (34%) of 129 and 36 (34%) of 106 patients in the honey and standard care groups, respectively, had a positive skin culture (P = 0.98).
0	3682318	1538	1572	Median levels of skin colonization	Median levels of skin colonization at the last sampling were 1 (0 to 2.84) and 1 (0 to 2.70) log colony-forming units (CFUs)/swab for the honey and control groups, respectively (P = 0.94).
0	3682318	1899	1923	skin-culture positivity.	Correction for these variables did not change the effect of honey on skin-culture positivity.  
0	3682318	1973	1997	colonization of the skin	Conclusions Medical-grade honey does not affect colonization of the skin at CVC insertion sites in intensive care unit patients when applied in addition to standard disinfection with 0.5% chlorhexidine in 70% alcohol.  
0	3685780	1105	1128	Systolic blood pressure	Results: Systolic blood pressure decreased significantly in aspart group (P = 0.008) whereas diastolic blood pressure was decreased significantly both in aspart (P < 0.001) and lispro group (P = 0.01).
0	3685780	1189	1213	diastolic blood pressure	Results: Systolic blood pressure decreased significantly in aspart group (P = 0.008) whereas diastolic blood pressure was decreased significantly both in aspart (P < 0.001) and lispro group (P = 0.01).
0	3685780	1298	1343	Fasting, postprandial blood glucose and HbA1c	Fasting, postprandial blood glucose and HbA1c were decreased in all three groups significantly but change in aspart group was superior (P = 0.01).
0	3685780	1445	1457	Triglyceride	Triglyceride was significantly better controlled by lispro (P < 0.01) whereas aspart insulin was superior to decrease total cholesterol and LDL (P < 0.05).
0	3685780	1563	1588	total cholesterol and LDL	Triglyceride was significantly better controlled by lispro (P < 0.01) whereas aspart insulin was superior to decrease total cholesterol and LDL (P < 0.05).
0	3685780	1615	1629	potassium loss	The extent of potassium loss was significantly more with regular human insulin (P = 0.004) than others.
0	3685780	1705	1724	CRP-lowering effect	CRP-lowering effect (P = 0.017) and decrease in UKPDS risk scoring (P = 0.019) in aspart and lispro group was superior to regular human insulin group.  
0	3685780	1750	1771	in UKPDS risk scoring	CRP-lowering effect (P = 0.017) and decrease in UKPDS risk scoring (P = 0.019) in aspart and lispro group was superior to regular human insulin group.  
0	4584965	1039	1059	metabolic parameters	Results The dietary intervention significantly influenced several metabolic parameters compared to base line.
0	4584965	1108	1155	reduced mean postprandial plasma glucose levels	Inzone Preload treatment reduced mean postprandial plasma glucose levels (12.2 ± 1.2 vs. 10.5 ± 2.0 mmol/L), HbA1c (7.4 ± 0.3 vs. 7.1 ± 0.2%), mean total cholesterol (4.8 ± 0.9 vs. 4.3 ± 0.8 mmol/L), low-density lipoprotein cholesterol (2.8 ± 0.6 vs. 2.5 ± 0.4 mmol/L), and CRP (1.5 ± 1.4 vs. 0.7 ± 0.7 mg/L).
0	4584965	1192	1197	HbA1c	Inzone Preload treatment reduced mean postprandial plasma glucose levels (12.2 ± 1.2 vs. 10.5 ± 2.0 mmol/L), HbA1c (7.4 ± 0.3 vs. 7.1 ± 0.2%), mean total cholesterol (4.8 ± 0.9 vs. 4.3 ± 0.8 mmol/L), low-density lipoprotein cholesterol (2.8 ± 0.6 vs. 2.5 ± 0.4 mmol/L), and CRP (1.5 ± 1.4 vs. 0.7 ± 0.7 mg/L).
0	4584965	1223	1248	), mean total cholesterol	Inzone Preload treatment reduced mean postprandial plasma glucose levels (12.2 ± 1.2 vs. 10.5 ± 2.0 mmol/L), HbA1c (7.4 ± 0.3 vs. 7.1 ± 0.2%), mean total cholesterol (4.8 ± 0.9 vs. 4.3 ± 0.8 mmol/L), low-density lipoprotein cholesterol (2.8 ± 0.6 vs. 2.5 ± 0.4 mmol/L), and CRP (1.5 ± 1.4 vs. 0.7 ± 0.7 mg/L).
0	4584965	1280	1318	), low-density lipoprotein cholesterol	Inzone Preload treatment reduced mean postprandial plasma glucose levels (12.2 ± 1.2 vs. 10.5 ± 2.0 mmol/L), HbA1c (7.4 ± 0.3 vs. 7.1 ± 0.2%), mean total cholesterol (4.8 ± 0.9 vs. 4.3 ± 0.8 mmol/L), low-density lipoprotein cholesterol (2.8 ± 0.6 vs. 2.5 ± 0.4 mmol/L), and CRP (1.5 ± 1.4 vs. 0.7 ± 0.7 mg/L).
0	4584965	1353	1360	and CRP	Inzone Preload treatment reduced mean postprandial plasma glucose levels (12.2 ± 1.2 vs. 10.5 ± 2.0 mmol/L), HbA1c (7.4 ± 0.3 vs. 7.1 ± 0.2%), mean total cholesterol (4.8 ± 0.9 vs. 4.3 ± 0.8 mmol/L), low-density lipoprotein cholesterol (2.8 ± 0.6 vs. 2.5 ± 0.4 mmol/L), and CRP (1.5 ± 1.4 vs. 0.7 ± 0.7 mg/L).
0	4584965	1393	1409	Body weight loss	Body weight loss of more than 3% was seen in 13 participants (43%).
0	4584965	1461	1480	Feelings of satiety	Feelings of satiety were significantly higher after Inzone Preload than after habitual breakfast (p < 0.05).
0	4584965	1596	1690	fasting blood glucose, high-density lipoprotein and total triacylglycerol, HOMA-IR, and HOMA-β	No significant changes in fasting blood glucose, high-density lipoprotein and total triacylglycerol, HOMA-IR, and HOMA-β were observed.  
0	4584965	1761	1821	postprandial glucose, inflammatory markers, and serum lipids	Conclusion A macro-nutrient preload treatment reduces postprandial glucose, inflammatory markers, and serum lipids in patients with type 2 diabetes mellitus.
0	4584965	1918	1938	reduced Body weight.	Approximately half of the study group also displayed reduced Body weight.
0	5892002	1175	1205	EQ-VAS significantly increased	Results The EQ-VAS significantly increased within the intervention group (mean difference 2.19, p = 0.005).
0	5892002	1310	1316	EQ-VAS	There was no significant difference in EQ-VAS between groups (mean difference 1.00, p = 0.339).
0	5892002	1686	1698	final EQ-VAS	In multilevel modeling, sex, age, family and work circumstances, any macrovascular diabetic complication, duration of diabetes, baseline body mass index and baseline EQ-VAS significantly influence final EQ-VAS, while disease management programme does not.
0	5892002	1854	1867	patient-level	Most of the unexplained variance was found on patient-level (95%) and less on GP-level (5%).  
0	5892002	1886	1894	GP-level	Most of the unexplained variance was found on patient-level (95%) and less on GP-level (5%).  
0	5892002	1988	2001	final EQ-VAS.	Therapie-Aktiv” has no significant impact on final EQ-VAS.
0	5850666	1375	1393	diastolic function	In the astragalus membranaceus Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity (E’; 0.065 ± 0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity (E/A; 0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), the ratio of E’ to the late diastolic mitral annular velocity (E’/A’; 0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), and the ratio of the early diastolic mitral peak flow velocity (E) to E’ (E/E’; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031).
0	5850666	1453	1506	including the early diastolic mitral annular velocity	In the astragalus membranaceus Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity (E’; 0.065 ± 0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity (E/A; 0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), the ratio of E’ to the late diastolic mitral annular velocity (E’/A’; 0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), and the ratio of the early diastolic mitral peak flow velocity (E) to E’ (E/E’; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031).
0	5850666	1553	1671	P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity	In the astragalus membranaceus Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity (E’; 0.065 ± 0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity (E/A; 0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), the ratio of E’ to the late diastolic mitral annular velocity (E’/A’; 0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), and the ratio of the early diastolic mitral peak flow velocity (E) to E’ (E/E’; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031).
0	5850666	1732	1756	E’ to the late diastolic	In the astragalus membranaceus Group 2, significant improvements were noted in diastolic function 12 months after treatment than those of the control group, including the early diastolic mitral annular velocity (E’; 0.065 ± 0.007 m/s vs. 0.061 ± 0.008 m/s, P = 0.014), the ratio of the early diastolic mitral peak flow velocity to the late diastolic mitral peak flow velocity (E/A; 0.81 ± 0.05 vs. 0.80 ± 0.06, P = 0.012), the ratio of E’ to the late diastolic mitral annular velocity (E’/A’; 0.56 ± 0.12 vs. 0.51 ± 0.13, P = 0.048), and the ratio of the early diastolic mitral peak flow velocity (E) to E’ (E/E’; 10.70 ± 1.30 vs. 11.37 ± 1.73, P = 0.031).
0	5850666	2016	2031	), deceleration	After treatment, E/E’ (10.70 ± 1.30 vs. 11.24 ± 1.56, P = 0.021), deceleration time (DT; 261.49 ± 44.41 ms vs. 268.74 ± 53.87 ms, P = 0.046), and E’/A’ (0.56 ± 0.12 vs. 0.52 ± 0.13, P = 0.019) values improved more significantly than those of astragalus membranaceus Group 2 before treatment.
0	5850666	2245	2273	Besides, waist circumference	Besides, waist circumference was positively correlated with E’ (r = 0.472; P = 0.003) and E’/A’ (r = 0.321; P = 0.047).
0	5850666	2329	2339	) and E’/A	Besides, waist circumference was positively correlated with E’ (r = 0.472; P = 0.003) and E’/A’ (r = 0.321; P = 0.047).
0	5850666	2362	2364	).	Besides, waist circumference was positively correlated with E’ (r = 0.472; P = 0.003) and E’/A’ (r = 0.321; P = 0.047).
0	5850666	2365	2400	In addition, the waist-to-hip ratio	In addition, the waist-to-hip ratio was a significant predictor of DT (r = 0.276; P = 0.041), E’ (r = −0.590; P < 0.001), E/E’ (r = 0.454; P = 0.004), and E’/A’ (r = −0.377; P = 0.018).  
0	5850666	2539	2550	P = 0.018).	In addition, the waist-to-hip ratio was a significant predictor of DT (r = 0.276; P = 0.041), E’ (r = −0.590; P < 0.001), E/E’ (r = 0.454; P = 0.004), and E’/A’ (r = −0.377; P = 0.018).  
0	5850666	2632	2651	diastolic function.	Conclusions: Conventional medical plus astragalus membranaceus therapy improved diastolic function.
0	3728070	1099	1128	genotyping-adjusted cure rate	Results The day 42 genotyping-adjusted cure rate estimates were 97.3% [95% CI: 91.6-99.1] for artesunate-amodiaquine and 94.2% [88.1-97.2] for artemether-lumefantrine (Kaplan-Meier survival estimates).
0	3728070	1307	1317	cure rates	The difference in day 42 cure rates was −3.1% [upper limit 95% CI: 1.2%].
0	3728070	1468	1486	Parasite clearance	Parasite clearance was 100% (artesunate-amodiaquine) and 99.3% (artemether-lumefantrine) on day 3.
0	3728070	1571	1613	probability to remain free of re-infection	The probability to remain free of re-infection was 0.55 [95% CI: 0.46-0.63] (artesunate-amodiaquine) and 0.66 [0.57-0.73] (artemether-lumefantrine) (p = 0.017).  
0	3728070	1897	1937	proportion of patients with re-infection	The proportion of patients with re-infection was high in both arms in this highly endemic setting.
0	5435072	1051	1074	Results Mean gastric pH	Results Mean gastric pH in the cats that received omeprazole was 7.2 ± 0.4 (range, 6.6–7.8) and was significantly higher than the pH in cats that received the placebo 2.8 ± 1.0 (range, 1.3–4.1; P < .001).
0	5435072	1332	1359	serum gastrin concentration	Omeprazole administration was not associated with a significant increase in serum gastrin concentration (P = .616).
0	5435072	1403	1437	episode of Gastroesophageal reflux	Nine of 27 cats (33.3%) had ≥1 episode of Gastroesophageal reflux during anesthesia.  
0	5435072	1624	1661	increase in gastric and esophageal pH	Conclusions and Clinical Relevance Pre‐anesthetic administration of 2 PO doses of omeprazole at a dosage of 1.45–2.20 mg/kg in cats was associated with a significant increase in gastric and esophageal pH within 24 hours, but was not associated with a significant increase in serum gastrin concentration.
0	5435072	1733	1761	serum gastrin concentration.	Conclusions and Clinical Relevance Pre‐anesthetic administration of 2 PO doses of omeprazole at a dosage of 1.45–2.20 mg/kg in cats was associated with a significant increase in gastric and esophageal pH within 24 hours, but was not associated with a significant increase in serum gastrin concentration.
0	5435072	1762	1789	Prevalence of reflux events	Prevalence of reflux events in cats during anesthesia was similar to that of dogs during anesthesia.
0	3621778	1188	1194	length	The intervention did not show statistically significant effects on length, but point estimates found were in the desired direction: mean difference 0.21 (95%CI −0.02; 0.44) for length-for-age Z-score and OR 0.50 (95%CI 0.22; 1.10) for stunting.
0	3621778	1298	1320	length-for-age Z-score	The intervention did not show statistically significant effects on length, but point estimates found were in the desired direction: mean difference 0.21 (95%CI −0.02; 0.44) for length-for-age Z-score and OR 0.50 (95%CI 0.22; 1.10) for stunting.
0	3621778	1356	1365	stunting.	The intervention did not show statistically significant effects on length, but point estimates found were in the desired direction: mean difference 0.21 (95%CI −0.02; 0.44) for length-for-age Z-score and OR 0.50 (95%CI 0.22; 1.10) for stunting.
0	3621778	1389	1411	of BMI-for-age Z-score	Significant reductions of BMI-for-age Z-score (−0.31, 95%CI −0.49; -0.12) and of BMI-for-age > 85th percentile (0.43, 95%CI 0.23; 0.77) were observed.
0	3621778	1447	1465	BMI-for-age > 85th	Significant reductions of BMI-for-age Z-score (−0.31, 95%CI −0.49; -0.12) and of BMI-for-age > 85th percentile (0.43, 95%CI 0.23; 0.77) were observed.
0	3621778	1609	1738	growth monitoring, health promotion activities, micronutrient supplementation, exclusive breastfeeding and complementary feeding.	The intervention showed positive effects in some indicators of intermediary factors such as growth monitoring, health promotion activities, micronutrient supplementation, exclusive breastfeeding and complementary feeding.  
0	1660570	1006	1025	Withdrawal symptoms	Withdrawal symptoms were reduced in both groups, but only the BPN/VPA group achieved a reduction in withdrawal symptoms from day one.
0	1660570	1106	1125	withdrawal symptoms	Withdrawal symptoms were reduced in both groups, but only the BPN/VPA group achieved a reduction in withdrawal symptoms from day one.
0	1660570	1364	1441	blood pressure, pulse or liver function, and the total burden of side-effects	The BPN/VPA combination did not affect blood pressure, pulse or liver function, and the total burden of side-effects was experienced as modest.
0	1660570	1493	1521	pharmacological interactions	There appeared to be no pharmacological interactions of clinical concern, based on measurement of Buprenorphine and Valproate serum levels.
0	3757791	696	718	Surgical field quality	Results: Surgical field quality after 15 min revealed that seven patients in group I had minimal bleeding versus no one in group II, P=0.006.
0	3757791	776	792	minimal bleeding	Results: Surgical field quality after 15 min revealed that seven patients in group I had minimal bleeding versus no one in group II, P=0.006.
0	3757791	867	880	mild bleeding	Meanwhile, 35 patients in group I had mild bleeding versus 26 patients in group II, P=0.064.
0	3757791	980	997	moderate bleeding	Higher number of patients in group II than in group I had moderate bleeding, P=0006.
0	3757791	1065	1081	minimal bleeding	Also, at 30 min, revealed that 10 patients in group I had minimal bleeding versus one patient in group II, P=0.004.
0	3757791	1161	1174	mild bleeding	Meanwhile, 37 patients in group I had mild bleeding versus 28 patients in group II, P=0.059.
0	3757791	1274	1291	moderate bleeding	Higher number of patients in group II than in group I had moderate bleeding, P<0001.
0	3757791	1301	1349	Duration of the surgeries and volume of bleeding	Duration of the surgeries and volume of bleeding were significantly less in tranexamic group than the placebo group, P<0.0001.  
0	3493833	602	646	live birth rate and clinical pregnancy rate.	RESULTS: There was no significant difference in live birth rate and clinical pregnancy rate.
0	3493833	647	688	Rate of ovarian hyperstimulation syndrome	Rate of ovarian hyperstimulation syndrome was significantly higher in the agonist group.
0	3493833	736	810	Number of oocytes retrieved, number of follicles and peak estradiol levels	Number of oocytes retrieved, number of follicles and peak estradiol levels were significantly more in the agonist group.  
0	3590693	1183	1218	Mean score of total quality of life	Mean score of total quality of life (p < 0.001 in both groups), mean score of quality of life in vasomotor domain (p < 0.001 in both groups), psycho-social domain (p < 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p < 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values.
0	3590693	1247	1296	mean score of quality of life in vasomotor domain	Mean score of total quality of life (p < 0.001 in both groups), mean score of quality of life in vasomotor domain (p < 0.001 in both groups), psycho-social domain (p < 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p < 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values.
0	3590693	1325	1345	psycho-social domain	Mean score of total quality of life (p < 0.001 in both groups), mean score of quality of life in vasomotor domain (p < 0.001 in both groups), psycho-social domain (p < 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p < 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values.
0	3590693	1406	1421	physical domain	Mean score of total quality of life (p < 0.001 in both groups), mean score of quality of life in vasomotor domain (p < 0.001 in both groups), psycho-social domain (p < 0.001 in red clover and p = 0.02 in placebo group) and physical domain (p < 0.001 red clover and p = 0.01 placebo group) significantly reduced compared to the baseline values.
0	3590693	1600	1621	total quality of life	However, the differences between two groups were significant neither for total quality of life nor for its domains.
0	3590693	1661	1673	side effects	Red clover had no side effects and all the subjects in the red clover group were satisfied with the prescribed administration Conclusions: In the present study, the effect of red clover supplementation on menopausal women's quality of life showed no difference with the placebo.
0	5769199	1499	1588	heart rate, systolic blood pressure, diastolic blood pressure, and Perceived Stress Scale	Results: heart rate, systolic blood pressure, diastolic blood pressure, and Perceived Stress Scale decreased significantly (P < 0.05) in the study group following 12 weeks slow breathing exercise training, while no significant change (P > 0.05) was observed in body mass index and waist-hip ratio.
0	5769199	1912	1928	perceived stress	Conclusion: Twelve weeks of modified slow breathing exercise reduced perceived stress and improved the cardiovascular parameters.
0	5769199	1946	1972	cardiovascular parameters.	Conclusion: Twelve weeks of modified slow breathing exercise reduced perceived stress and improved the cardiovascular parameters.
0	4033489	1182	1196	adverse events	No dose response in adverse events was observed but a trend towards more patients having at least one AE across canakinumab groups relative to placebo (P = 0.0152) was observed.
0	4033489	1340	1351	serious AEs	serious AEs were few and the incidence rate for most canakinumab groups was lower than that of placebo group except for the high-dose group (0.94% versus 0.58% per month in placebo).
0	4033489	1369	1383	incidence rate	serious AEs were few and the incidence rate for most canakinumab groups was lower than that of placebo group except for the high-dose group (0.94% versus 0.58% per month in placebo).
0	4033489	1621	1626	death	No death was reported in any of the three studies.
0	4033489	1710	1752	incidence rate of infection adverse events	A small, non-significant increase in the incidence rate of infection adverse events was observed on canakinumab groups relative to placebo.
0	4033489	1866	1903	WBC, neutrophils and platelet counts.	Canakinumab was associated with mostly mild decreases in WBC, neutrophils and platelet counts.
0	4033489	1936	1960	SGPT, SGOT and bilirubin	Additionally, mild increases in SGPT, SGOT and bilirubin were reported.
0	4033489	2074	2108	laboratory values and vital signs.	Overall, despite small differences, no clinically relevant findings were observed with respect to laboratory values and vital signs.  
0	3636802	1590	1603	visits to the	Results Adjusting for baseline readiness to quit, persons who received content written in a prescriptive tone made the same number of visits to the website as persons receiving content in a motivational tone, but viewed 1.17 times as many content areas (95% CI 1.08-1.28; P<.001) and 1.15 times as many pages (95% CI 1.04-1.28; P=.009).
0	3636802	1793	1821	Time spent viewing materials	Time spent viewing materials did not differ among groups (P=.06).
0	3636802	1967	1983	number of visits	Persons required to view content in a dictated order based on their initial readiness to quit made the same number of visits as people able to freely navigate the site, but viewed fewer content areas (ratio of means 0.80, 95% CI 0.74-0.87; P<.001), 1.17 times as many pages (95% CI 1.06-1.31; P=.003), and spent 1.37 times more minutes online (95% CI 1.17-1.59; P<.001).
0	3636802	2127	2132	pages	Persons required to view content in a dictated order based on their initial readiness to quit made the same number of visits as people able to freely navigate the site, but viewed fewer content areas (ratio of means 0.80, 95% CI 0.74-0.87; P<.001), 1.17 times as many pages (95% CI 1.06-1.31; P=.003), and spent 1.37 times more minutes online (95% CI 1.17-1.59; P<.001).
0	3636802	2187	2201	minutes online	Persons required to view content in a dictated order based on their initial readiness to quit made the same number of visits as people able to freely navigate the site, but viewed fewer content areas (ratio of means 0.80, 95% CI 0.74-0.87; P<.001), 1.17 times as many pages (95% CI 1.06-1.31; P=.003), and spent 1.37 times more minutes online (95% CI 1.17-1.59; P<.001).
0	3636802	2298	2304	visits	Persons receiving proactive email reminders made 1.20 times as many visits (95% CI 1.09-1.33; P<.001), viewed a similar number of content areas as persons receiving no reminders, viewed 1.58 times as many pages (95% CI 1.48-1.68; P<.001), and spent 1.51 times as many minutes online (95% CI 1.29-1.77; P<.001) as those who did not receive proactive emails.
0	3636802	2350	2373	number of content areas	Persons receiving proactive email reminders made 1.20 times as many visits (95% CI 1.09-1.33; P<.001), viewed a similar number of content areas as persons receiving no reminders, viewed 1.58 times as many pages (95% CI 1.48-1.68; P<.001), and spent 1.51 times as many minutes online (95% CI 1.29-1.77; P<.001) as those who did not receive proactive emails.
0	3636802	2435	2440	pages	Persons receiving proactive email reminders made 1.20 times as many visits (95% CI 1.09-1.33; P<.001), viewed a similar number of content areas as persons receiving no reminders, viewed 1.58 times as many pages (95% CI 1.48-1.68; P<.001), and spent 1.51 times as many minutes online (95% CI 1.29-1.77; P<.001) as those who did not receive proactive emails.
0	3636802	2498	2512	minutes online	Persons receiving proactive email reminders made 1.20 times as many visits (95% CI 1.09-1.33; P<.001), viewed a similar number of content areas as persons receiving no reminders, viewed 1.58 times as many pages (95% CI 1.48-1.68; P<.001), and spent 1.51 times as many minutes online (95% CI 1.29-1.77; P<.001) as those who did not receive proactive emails.
0	3636802	2638	2649	engagement.	Tailored testimonials did not significantly affect engagement.  
0	3636802	2784	2802	program engagement	Conclusions Using a prescriptive message tone, dictating content viewing order, and sending reminder emails each resulted in greater program engagement relative to the contrasting level of each experimental factor.
0	4809130	909	970	reduction of serum high-sensitivity C-reactive protein levels	Results: Consumption of calcium-Vitamin D co-supplements resulted in a significant reduction of serum high-sensitivity C-reactive protein levels compared with placebo (−1856.8 ± 2657.7 vs. 707.1 ± 3139.4 μg/mL, P = 0.006).
0	4809130	1077	1123	elevation of plasma total antioxidant capacity	We also found a significant elevation of plasma total antioxidant capacity (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.03), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P < 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P < 0.0001).
0	4809130	1163	1199	P = 0.03), serum 25-hydroxyvitamin D	We also found a significant elevation of plasma total antioxidant capacity (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.03), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P < 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P < 0.0001).
0	4809130	1233	1264	P < 0.0001), and calcium levels	We also found a significant elevation of plasma total antioxidant capacity (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.03), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P < 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P < 0.0001).
0	4809130	1298	1310	P < 0.0001).	We also found a significant elevation of plasma total antioxidant capacity (89.3 ± 118.0 vs. −9.4 ± 164.9 mmol/L, P = 0.03), serum 25-hydroxyvitamin D (2.5 ± 3.5 vs. −1.7 ± 1.7 ng/mL, P < 0.0001), and calcium levels (0.6 ± 0.6 vs. −0.1 ± 0.4 mg/dL, P < 0.0001).
0	4809130	1352	1388	decrease in diastolic blood pressure	The supplementation led to a significant decrease in diastolic blood pressure (−1.9 ± 8.3 vs. 3.1 ± 5.2 mmHg, P = 0.02) compared with placebo.
0	4809130	1608	1626	pregnancy outcomes	We saw no significant change of the co-supplementation on pregnancy outcomes as well.  
0	4809130	1738	1765	improved metabolic profiles	Conclusions: Although calcium-Vitamin D co-supplementation for 9 weeks in pregnant women resulted in improved metabolic profiles, it did not affect pregnancy outcomes.
0	60660	1220	1239	serum folate levels	Results At all times of blood collection the differences between serum folate levels were insignificant (P > 0.05), except of the non-exposed controls at T2 (P < 0.05).
0	60660	1371	1384	folate levels	We did not observed significant differences of folate levels between UVA exposed and non-exposed volunteers (P > 0.05).  
0	60660	1547	1566	serum folate levels	Conclusions Our data suggest that both single and serial UVA exposures do not significantly influence serum folate levels of healthy subjects.
0	4132095	1329	1365	circulating selenium concentrations.	Results At end of surgery, both groups showed a comparable decrease of circulating selenium concentrations.
0	4132095	1376	1420	levels of oxidative stress and interleukin-6	Likewise, levels of oxidative stress and interleukin-6 were comparable in both groups.
0	5815470	955	981	visual analog scale score.	Results No significant differences were found between the two groups concerning age, sex, or baseline visual analog scale score.
0	5815470	1072	1095	deeper analgesic effect	From the 10th minute until the end of the intervention, acupuncture was associated with a deeper analgesic effect than titrated morphine (P<0.05 from the 10th minute and over).
0	5815470	1159	1168	Analgesia	Analgesia was also faster in the acupuncture group, with time to obtain 50% reduction of baseline visual analog scale of 14 minutes in the acupuncture group versus 28 minutes in the intravenous titrated-morphine group (P<0.001).
0	5815470	1248	1276	baseline visual analog scale	Analgesia was also faster in the acupuncture group, with time to obtain 50% reduction of baseline visual analog scale of 14 minutes in the acupuncture group versus 28 minutes in the intravenous titrated-morphine group (P<0.001).
0	5815470	1445	1463	minor side effects	Only three patients in the acupuncture group experienced minor side effects versus 42 in the morphine group (P<0.001).
0	5815470	1510	1528	major side effects	No major side effects were observed in this study.  
0	5951773	1030	1059	first and second test results	Results There was a small but significant decline in first and second test results for both groups (F(1, 135) = 18.154, p = 0.00).
0	5951773	1147	1191	short-term and long-term knowledge retention	However, no significant differences in short-term and long-term knowledge retention were observed between the two teaching methods.
0	5951773	1282	1308	learning experience levels	The Virtual Patient group reported higher learning experience levels in engagement, stimulation, general perception, and expectations.  
0	3531527	1335	1351	Demographic data	Results Demographic data and duration of anesthesia were not different between the two groups.
0	3531527	1499	1602	hemodynamic variables, respiratory variables, and inspiratory and expiratory desflurane concentrations.	Significant differences were not observed between the two groups in terms of hemodynamic variables, respiratory variables, and inspiratory and expiratory desflurane concentrations.
0	3531527	1603	1631	Inspiratory O2 concentration	Inspiratory O2 concentration was maintained lower in the minimal-flow group than in the high-flow group (43-53% vs. 53-59%; P < 0.05).
0	3531527	1771	1805	, carboxyhemoglobin concentrations	Compared with the high-flow group, carboxyhemoglobin concentrations was higher (P < 0.05), but not increased from the baseline value in the minimal-flow group.
0	3531527	1898	1993	Serum aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and creatinine	Serum aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, and creatinine were not significantly different between the two groups.  
0	3531527	2140	2159	safety and efficacy	Conclusions In prolonged laparoscopic surgery, no significant differences were found in safety and efficacy between minimal-flow and high-flow desflurane anesthesia.
0	4419514	1205	1224	The intubation time	Results The intubation time of group A was shorter than that of group G (36.6 ± 20.2 s vs. 54.6 ± 25.7 s, p = 0.002).
0	4419514	1312	1314	).	Results The intubation time of group A was shorter than that of group G (36.6 ± 20.2 s vs. 54.6 ± 25.7 s, p = 0.002).
0	4419514	1319	1339	Cormack-Lehane grade	The Cormack-Lehane grade (I/II/III/IV) was significantly better in group A (33/2/0/0 vs. 28/7/0/0, p = 0.042).
0	4419514	1430	1467	mean arterial pressure and heart rate	The mean arterial pressure and heart rate rose to higher levels during intubation with the GlideScope than with the Airtraq laryngoscope.
0	4419514	1568	1607	success of the first intubation attempt	The success of the first intubation attempt and the intubation difficulty scales were comparable between the two groups.
0	4419514	1616	1644	intubation difficulty scales	The success of the first intubation attempt and the intubation difficulty scales were comparable between the two groups.
0	4419514	1725	1750	postoperative sore throat	The numbers of patients who experienced postoperative sore throat were similar (6 vs. 8) in the two groups.  
0	3024329	802	841	Median time of maintaining the A1C goal	Median time of maintaining the A1C goal was 16.8 months for LM75/25 (95% CI 14.0–19.7) and 14.4 months for glargine (95% CI 13.4–16.8; P = 0.040).
0	3024329	949	957	A1C goal	A1C goal was maintained in 202 LM75/25-treated patients (43%) and in 147 glargine-treated patients (35%; P = 0.006).
0	3024329	1098	1141	overall, nocturnal, or severe hypoglycemia.	No differences were observed in overall, nocturnal, or severe hypoglycemia.
0	3024329	1163	1194	higher total daily insulin dose	LM75/25 patients had higher total daily insulin dose (0.45 ± 0.21 vs. 0.37 ± 0.21 units/kg/day) and more weight gain (5.4 ± 5.8 vs. 3.7 ± 5.6 kg) from baseline.
0	3024329	1242	1258	more weight gain	LM75/25 patients had higher total daily insulin dose (0.45 ± 0.21 vs. 0.37 ± 0.21 units/kg/day) and more weight gain (5.4 ± 5.8 vs. 3.7 ± 5.6 kg) from baseline.
0	3024329	1360	1363	A1C	Patients taking LM75/25 and glargine with lower baseline A1C levels were more likely to maintain the A1C goal (P = 0.043 and P < 0.001, respectively).  
0	3024329	1391	1412	maintain the A1C goal	Patients taking LM75/25 and glargine with lower baseline A1C levels were more likely to maintain the A1C goal (P = 0.043 and P < 0.001, respectively).  
0	3024329	1485	1515	durability of glycemic control	CONCLUSIONS A modestly longer durability of glycemic control was achieved with LM75/25 compared with glargine.
0	5801522	1707	1720	trait anxiety	Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students, and more participants in the experimental condition believed their productivity improved between baseline and postintervention measurements than the number of participants expected to believe so randomly by chance (P=.01).
0	5801522	1741	1755	general health	Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students, and more participants in the experimental condition believed their productivity improved between baseline and postintervention measurements than the number of participants expected to believe so randomly by chance (P=.01).
0	5801522	1766	1772	energy	Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students, and more participants in the experimental condition believed their productivity improved between baseline and postintervention measurements than the number of participants expected to believe so randomly by chance (P=.01).
0	5801522	1786	1806	emotional well-being	Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students, and more participants in the experimental condition believed their productivity improved between baseline and postintervention measurements than the number of participants expected to believe so randomly by chance (P=.01).
0	5801522	1906	1918	productivity	Using DeStressify was shown to reduce trait anxiety (P=.01) and improve general health (P=.001), energy (P=.01), and emotional well-being (P=.01) in university students, and more participants in the experimental condition believed their productivity improved between baseline and postintervention measurements than the number of participants expected to believe so randomly by chance (P=.01).
0	5801522	2092	2176	improve stress, state anxiety, physical and social functioning, and role limitations	The app did not significantly improve stress, state anxiety, physical and social functioning, and role limitations because of physical or emotional health problems or pain (P>.05).  
0	3685784	1039	1052	Pain severity	Results: Pain severity was reduced in both herbal and classic groups with no significant differences.
0	3685784	1132	1145	Pain duration	Pain duration at the first and second month of treatment was also similar between two groups.  
0	5752785	1249	1279	central venous catheterisation	Results: central venous catheterisation was achieved in 98% (49/50) of patients in study group and 80% (40/50) of patients in control group (P = 0.008).
0	5752785	1393	1418	Mean catheterisation time	Mean catheterisation time was significantly lower in the study group (151.06 ± 40.50 s) compared to control group (173.50 ± 50.66 s) (P = 0.023).
0	5752785	1543	1602	incidence of catheter misplacement and failure to cannulate	The incidence of catheter misplacement and failure to cannulate were lower in the study group (0%, 2% vs. 20%, 12.5%, respectively).
0	5752785	1699	1761	number of catheterisation attempts and incidence of haematoma.	Groups did not differ in a number of catheterisation attempts and incidence of haematoma.  
0	5752785	1862	1874	success rate	Conclusion: Inclusion of various body manoeuvres to Seldinger technique significantly improves the success rate of central venous catheterisation through external jugular vein.
0	3562170	1338	1359	Results Blood glucose	Results Blood glucose was higher (p <  0.05) after 50 min of submaximal cycling just prior to the Wingate anaerobic tests for carbohydrate-electrolyte (6.1 ± 1.7 mmol/L) compared to water (4.9 ± 1.5 mmol/L) and non-caloric electrolyte (4.6 ± 1.2 mmol/L).
0	3562170	1436	1453	Wingate anaerobic	Results Blood glucose was higher (p <  0.05) after 50 min of submaximal cycling just prior to the Wingate anaerobic tests for carbohydrate-electrolyte (6.1 ± 1.7 mmol/L) compared to water (4.9 ± 1.5 mmol/L) and non-caloric electrolyte (4.6 ± 1.2 mmol/L).
0	3562170	2034	2048	) power output	Nonetheless, there were no differences among treatments in peak (642 ± 153, 635 ± 143, 650 ± 141 watts for water, non-caloric electrolyte, and carbohydrate-electrolyte, respectively; p  =  0.44) or mean (455 ± 100, 458 ± 95, 454 ± 95 watts for water, non-caloric electrolyte, and carbohydrate-electrolyte, respectively; p = 0.62) power for the first Wingate anaerobic tests or mean (414 ± 92, 425 ± 85, 423 ± 82 watts, respectively; p = 0.13) power output averaged across all 3 WAnT.
0	1523225	1660	1671	mean BISmin	The lowest mean BISmin was measured in group 1 (28.7 ± 10.3).
0	1523225	1708	1710	).	The lowest mean BISmin was measured in group 1 (28.7 ± 10.3).
0	1523225	2354	2376	hemodynamic parameters	The hemodynamic parameters were not significantly different among groups.  
0	1523225	2442	2462	hypnotic peak effect	Conclusions: The hypnotic peak effect of propofol is lower with extremely slow injection (240 s versus 5 s).
0	1523225	2627	2648	propofol peak effect.	For clinically usual injection rates (5 s and 120 s), there was no significant difference in propofol peak effect.
0	4776353	1053	1059	regret	Results A significantly greater proportion of the experimental group subjects reported regret played a role in their decision-making process compared to the control counterparts (78 vs. 65 %; p = 0.039).
